2024-01-31 00:36:26
Seoul, South Korea, Oct. 23, 2021 /PRNewswire/ — Seegene Inc. (KQ096530), a leading South Korean molecular PCR diagnostics company, announced in London on January 23 a strategic partnership with Microsoft for its SG OneSystemTM project To realize the vision of a “world without disease”.
The strategic cooperation in the field of molecular diagnostics aims to achieve a “world without diseases and future pandemics” Digital optimization of Seegene’s automated development system for diagnostic reagents through the integration of Microsoft Azure AI solutions The celebratory announcement will be made in the first half of 2024 the starting signal for the collaboration
Seegene will work with Microsoft to advance the development of the SG OneSystemTM project, Seegene’s unprecedented strategy to share its quantitative syndromic PCR technologies with leading companies around the world to promote cross-industry innovation in molecular diagnostics. The expansion of participating companies, with which Seegene aims to form a global consortium, will provide optimal solutions worldwide to effectively manage future pandemics, collectively moving closer to the goal of a “world without disease.”
To achieve this goal, Seegene is working with Microsoft’s global healthcare team to promote the SG OneSystemTM project by championing the shared vision and bringing together potential partners at the SG OneSystemTM annual symposium. Other important events bringing together current and potential SG OneSystemTM partners participating in the SG OneSystemTM project will take place in the first half of this year to realize the shared vision.
The Seegene Digitalized Development System (SGDDS) integrates Microsoft Azure services, such as: B. Azure OpenAI Service. This service is used by Seegene to simplify data interaction and analysis for researchers working with the large volume of data generated by the SGDDS. Implementing the highly secure Azure Trusted Research Environment (TRE) will expand the boundaries of PCR research and support compliance with both privacy and regulatory requirements. Seegene implements Microsoft Fabric, a central AI-powered analytics platform that unifies Seegene’s data and redesigns data access and management. It uses features that include data integration, data modeling, data science, data monitoring, real-time analytics and business intelligence. Integrating AI support using Microsoft 365 Copilot will increase productivity, drive innovation and improve creativity.
Seegene also collaborates with Microsoft on research for healthcare innovations. This includes next-generation management and analysis of PCR data as well as the initiation of future projects in the healthcare sector. Seegene’s goal, together with Microsoft, is to improve healthcare by accurately and early diagnosing diseases, which forms the basis for effective treatment and prevention.
“The strategic collaboration with Microsoft enables us to use a better structured SG OneSystemTM,” said Dr. Jong-Yoon Chun, CEO and founder of Seegene. “Through our joint efforts, we hope to achieve synergy effects that will pave the way to a world free of all diseases will pave the way.”
“We support Seegene’s vision of a ‘world without disease,'” said Elena Bonfiglioli, General Manager of Global Health and Life Sciences at Microsoft. “In addition to working with Seegene on the company’s digital transformation, we will collaborate to to find global partners and further improve the healthcare system.”
Information about Seegene
Seegene has 23 years of relevant experience in the research and development, manufacturing and operation of quantitative syndrome PCR technologies, which was particularly evident during the COVID-19 pandemic when the company completed more than 340 million COVID-19 tests delivered to over 100 countries worldwide. The core element of Seegene’s unique syndrome PCR technology is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single PCR approach and provide quantitative information about the infectivity profile that correlates with disease severity.
SG OneSystem TM project
The SG OneSystemTM project is a global strategy to achieve a “world without disease”. The goal is to enable scientists and experts to locally develop quantitative syndromic PCR diagnostic tests that detect diseases in all organisms and in all areas of application, with SGDDS being used in global cooperation.
Seegene aims to share its unique quantitative syndrome PCR technologies with leading companies around the world to partner with them as a consortium partner for the development, manufacturing and distribution of diagnostic tests. The SG OneSystemTM is designed to shift the effort to develop products that cover all diseases from a single company to a collaborative global network. This includes not only development, but also regulatory approval issues, manufacturing, marketing and sales. The success of SG OneSystemTM will provide a comprehensive prevention measure that contributes to a sustainable future for the entire ecosystem.
As part of SG OneSystemTM, Seegene launched the “Open Innovation Program powered by Seegene” together with Springer Nature in September 2023. As part of this program, experts, scientists and clinical staff can develop quantitative syndrome PCR assays for everyone Develop areas of application.
Questions & Contact:
Yoorim Kang,
[email protected]
1706667459
#Seegene #announces #collaboration #Microsoft #realize #vision #world #disease